Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Article metrics

Abstract

Human non–small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation. Genetic or pharmacological inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs. These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: AXL is overexpressed in EGFR-mutant NSCLC tumor xenografts with acquired resistance to erlotinib.
Figure 2: AXL overexpression is necessary for acquired resistance to erlotinib treatment in EGFR-mutant NSCLC tumors in vivo.
Figure 3: AXL upregulation is necessary and sufficient for acquired resistance to erlotinib in EGFR-mutant NSCLC cellular models.
Figure 4: AXL-mediated erlotinib resistance occurs in association with EMT in EGFR-mutant NSCLC cellular models.
Figure 5: AXL upregulation occurs in human EGFR-mutant NSCLCs with acquired resistance to EGFR TKIs.

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. 1

    Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).

  2. 2

    Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).

  3. 3

    Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

  4. 4

    Sordella, R., Bell, D.W., Haber, D.A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004).

  5. 5

    Jänne, P.A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709–723 (2009).

  6. 6

    Gazdar, A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361, 1018–1020 (2009).

  7. 7

    Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).

  8. 8

    Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).

  9. 9

    Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).

  10. 10

    Turke, A.B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77–88 (2010).

  11. 11

    Bivona, T.G. et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523–526 (2011).

  12. 12

    Arcila, M.E. et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid–based assay. Clin. Cancer Res. 17, 1169–1180 (2011).

  13. 13

    Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104, 20932–20937 (2007).

  14. 14

    Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).

  15. 15

    Linger, R.M., Keating, A.K., Earp, H.S. & Graham, D.K. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin. Ther. Targets 14, 1073–1090 (2010).

  16. 16

    Keating, A.K. et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol. Cancer Ther. 9, 1298–1307 (2010).

  17. 17

    Vuoriluoto, K. et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30, 1436–1448 (2011).

  18. 18

    Suda, K. et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor–mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 6, 1152–1161 (2011).

  19. 19

    Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254–5264 (2010).

  20. 20

    Qian, F. et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009–8016 (2009).

  21. 21

    Yun, C.H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 105, 2070–2075 (2008).

  22. 22

    Polyak, K. & Weinberg, R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265–273 (2009).

  23. 23

    Jackman, D. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28, 357–360 (2010).

  24. 24

    Burchert, A., Attar, E.C., McCloskey, P., Fridell, Y.W. & Liu, E.T. Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene 16, 3177–3187 (1998).

  25. 25

    Tai, K.Y., Shieh, Y.S., Lee, C.S., Shiah, S.G. & Wu, C.W. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1. Oncogene 27, 4044–4055 (2008).

  26. 26

    Azumi, N. & Battifora, H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am. J. Clin. Pathol. 88, 286–296 (1987).

  27. 27

    Chitale, D. et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28, 2773–2783 (2009).

  28. 28

    Rosell, R., Wei, J. & Taron, M. Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin. Lung Cancer 10, 8–9 (2009).

  29. 29

    Brevet, M., Arcila, M. & Ladanyi, M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J. Mol. Diagn. 12, 169–176 (2010).

Download references

Acknowledgements

The authors thank K. Shokat for assistance with structural modeling of the AXL gatekeeper mutation, W. Polkinghorn, J. Wongvipat and E. Chan for advice and technical assistance and S. Edelheit of the Case Genomics Center for technical assistance. This work was supported by the Korean Health Technology R&D Project (grant A102059 to J.C.L.), the US National Institutes of Health (K08 1K08CA154787 to T.G.B. and P01 CA129243 to M.L.), a Uniting Against Lung Cancer Research Award, a National Lung Cancer Partnership Young Investigator Award (to T.G.B.), a grant from the La Caixa Foundation (to R.R.) and an American Cancer Society Research Scholar Grant (RSG-08-303-01 to B.H.).

Author information

Z.Z., J.C.L., L.L., V.A., T.L., M.A.-R., X.W., A.D.L., J.K.R., Y.J.C., C.-M.C., Y.S.P., S.-W.K., D.H.L., J.-S.L., P.M. and T.G.B. performed in vitro experiments. J.C.L., V.O., S.J.J., Y.S.P. and C.C. analyzed clinical specimens. M.A. and T.G.B. analyzed clinical data. P.M. and T.G.B. performed in vivo experiments. W.S.K., P.C.M., M.L., T.J.B., V.A.M., C.S., P.M., M.T., R.R., B.H. and T.G.B. analyzed in vitro and in vivo data. B.H. and T.G.B. wrote the manuscript.

Correspondence to Balazs Halmos or Trever G Bivona.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–14 and Supplementary Tables 4 and 5 (PDF 11391 kb)

Supplementary Table 1

Gene expression changes observed in erlotinib resistant HCC827 tumor xenografts by combined analysis. (XLS 117 kb)

Supplementary Table 2

Gene expression changes observed in erlotinib resistant HCC827 tumor xenografts. (XLS 4588 kb)

Supplementary Table 3

Gene expression changes observed in erlotinib resistant HCC827 cell lines. (XLS 203 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading